Difference between revisions of "Lenvatinib (Lenvima)"
Jump to navigation
Jump to search
m |
m |
||
| Line 22: | Line 22: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
===[[Thyroid cancer, differentiated|Differentiated thyroid cancer]]=== | ===[[Thyroid cancer, differentiated|Differentiated thyroid cancer]]=== | ||
| − | * | + | *2015-02-13: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm434347.htm Approved] for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory [[Thyroid cancer, differentiated|differentiated thyroid cancer]]. ''(Initial approval; based on SELECT)'' |
===[[Endometrial cancer]]=== | ===[[Endometrial cancer]]=== | ||
| − | * | + | *2019-09-17: Accelerated approval in combination with [[Pembrolizumab (Keytruda)]] for the treatment of patients with advanced [[Endometrial cancer|endometrial carcinoma]] that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation. ''(Based on KEYNOTE-146)'' |
| − | ** | + | **2021-07-21: Converted to regular approval in combination with [[Pembrolizumab (Keytruda)]] for the treatment of patients with advanced [[Endometrial cancer|endometrial carcinoma]] that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation. ''(Based on KEYNOTE-775)'' |
===[[Hepatocellular carcinoma]]=== | ===[[Hepatocellular carcinoma]]=== | ||
| − | * | + | *2018-08-16: Approved for first-line treatment of patients with unresectable [[Hepatocellular_carcinoma|hepatocellular carcinoma (HCC)]]. ''(Based on REFLECT)'' |
===[[Renal cell carcinoma]]=== | ===[[Renal cell carcinoma]]=== | ||
| − | * | + | *2016-05-13: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501070.htm Approved] in combination with [[Everolimus (Afinitor)|everolimus]], for the treatment of advanced [[Renal cell carcinoma|renal cell carcinoma]] following one prior [[:Category:VEGFR_inhibitors|anti-angiogenic therapy]]. ''(Based on E7080-G000-205)'' |
| − | * | + | *2021-08-10: Approved in combination with [[Pembrolizumab (Keytruda)]] for first-line treatment of adult patients with advanced [[Renal cell carcinoma|renal cell carcinoma (RCC)]]. ''(Based on CLEAR)'' |
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | * | + | *2015-05-28: Initial authorization as Lenvima |
| − | * | + | *2016-08-25: Initial authorization as Kisplyx |
===[[Thyroid cancer, differentiated|Differentiated thyroid cancer]]=== | ===[[Thyroid cancer, differentiated|Differentiated thyroid cancer]]=== | ||
*Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, [[Thyroid cancer, differentiated|differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC)]], refractory to radioactive iodine (RAI). | *Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, [[Thyroid cancer, differentiated|differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC)]], refractory to radioactive iodine (RAI). | ||
===[[Hepatocellular carcinoma]]=== | ===[[Hepatocellular carcinoma]]=== | ||
*Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable [[Hepatocellular carcinoma|hepatocellular carcinoma (HCC)]] who have received no prior systemic therapy. | *Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable [[Hepatocellular carcinoma|hepatocellular carcinoma (HCC)]] who have received no prior systemic therapy. | ||
| + | ==History of changes in Health Canada indication== | ||
| + | *2019-09-20: Notice of compliance with conditions in combination with pembrolizumab, for the treatment of adult patients with advanced [[Endometrial cancer|endometrial carcinoma]] that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation. | ||
==Also known as== | ==Also known as== | ||
Revision as of 11:16, 30 March 2023
General information
Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases (RTKs), including: vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4); fibroblast growth factor (FGF) receptors FGFR1, FGFR2, FGFR3, and FGFR4; platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. Inhibition of these receptor tyrosine kinases interferes with cancer cells' proliferation and pathogenic angiogenesis.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.[1]
Diseases for which it is established
Diseases for which it is used
Patient drug information
- Lenvatinib (Lenvima) package insert[1]
- Lenvatinib (Lenvima) patient drug information (Chemocare)[4]
- Lenvatinib (Lenvima) patient drug information (UpToDate)[5]
History of changes in FDA indication
Differentiated thyroid cancer
- 2015-02-13: Approved for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. (Initial approval; based on SELECT)
Endometrial cancer
- 2019-09-17: Accelerated approval in combination with Pembrolizumab (Keytruda) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation. (Based on KEYNOTE-146)
- 2021-07-21: Converted to regular approval in combination with Pembrolizumab (Keytruda) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation. (Based on KEYNOTE-775)
Hepatocellular carcinoma
- 2018-08-16: Approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). (Based on REFLECT)
Renal cell carcinoma
- 2016-05-13: Approved in combination with everolimus, for the treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy. (Based on E7080-G000-205)
- 2021-08-10: Approved in combination with Pembrolizumab (Keytruda) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC). (Based on CLEAR)
History of changes in EMA indication
- 2015-05-28: Initial authorization as Lenvima
- 2016-08-25: Initial authorization as Kisplyx
Differentiated thyroid cancer
- Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
Hepatocellular carcinoma
- Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.
History of changes in Health Canada indication
- 2019-09-20: Notice of compliance with conditions in combination with pembrolizumab, for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.
Also known as
- Code name: E7080
- Brand name: Kisplyx, Lenvima
References
Categories:
- Drugs
- Oral medications
- VEGFR inhibitors
- FGFR inhibitors
- PDGFR inhibitors
- KIT inhibitors
- RET inhibitors
- Cholangiocarcinoma medications
- Endometrial cancer medications
- Hepatocellular carcinoma medications
- Renal cell carcinoma medications
- Thyroid cancer, differentiated medications
- FDA approved in 2015
- EMA approved in 2015